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A 69-year-old male presented with several painful erythe-
matous patches on both palms and trunk several days after 
receiving iopromide (Ultravist
Ⓡ, Shering, Berlin, Germany). 
A fixed drug eruption (FDE) due to iopromide was suspected 
clinically. However, at that time, the patch test with 
iopromide at the lesion site gave negative results. Three years 
later, the patient was mistakenly administered iopromide 
again and patches with vesicles recurred on the same sites as 
well as on the genitalia. This episode was repeated once 
again after 1 year. In all episodes, the skin lesion resolved 
after application of topical steroids. Although a patch test 
with iopromide was negative in our case, we made a 
diagnosis of FDE due to iopromide because the skin lesions 
occurred again at the previously involved area after 
re-exposure to iopromide. To date, only three cases of FDE 
caused by non-ionic monomers have been documented in 
the English literature. Herein, we report on an interesting 
case of FDE caused by iopromide. (Ann Dermatol 23(S1) S33
∼S35, 2011)
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INTRODUCTION
Fixed drug eruption (FDE) usually appears as bright or 
dusky red macules that may evolve into edematous 
plaques. FDE can develop from 30 minutes to several days 
after ingestion of medication
1. On re-challenge, the skin 
lesion occurred again on the same location. This is the 
reason why it has been called “fixed” drug eruption
2. FDE 
is most commonly associated with ibuprofen, sulfonamides, 
naproxen, barbiturates, and tetracyclines
1. In addition, due 
to increasingly widespread use of imaging diagnosis, FDE 
has recently been observed after administration of contrast 
medium according to the frequency of use of organic 
iodine contrast media
3,4. We present an interesting case of 
recurrent FDE diagnosed after administration of iopromide 
despite negative results in patch testing.
CASE REPORT
A 69-year-old male patient suffering from non-ST-elevation 
myocardial infarction was referred to our department on 
May 14, 2005. He developed several painful, annular, 
erythematous patches on both palms and trunk several 
days after receiving iopromide (Ultravist
Ⓡ, Shering, Berlin, 
Germany) for percutaneous transluminal angioplasty 
(PTA). He had undergone PTA four times using iopromide 
(Ultravist
Ⓡ, Shering, Berlin, Germany) from October 10, 
2003 to May 13, 2005 and showed no adverse effect of 
the skin until then. A FDE due to iopromide was suspected 
clinically. The skin lesion was treated with topical 
methylprednisolone and desoxymethasone and showed 
complete resolution. One month later, we conducted a 
patch test with iopromide (as is, 1/3, 1/5, 1/10, and 1/100 
in 0.9% normal saline) and control (0.9% normal saline) 
on the lesion and normal skin. However, results of the 
patch test with iopromide on both sites were negative at 
48 hours and 96 hours. On November 26, 2008, the SH Cha, et al
S34 Ann Dermatol
Fig. 1. Clinical features of the second
episode: painful erythematous patches
on both palms and trunk several days
after receiving iopromide (Ultravist
Ⓡ,
Shering, Berlin, Germany).
Fig. 2. Clinical features of the third 
episode: skin lesions on the same 
area and also on the left arm after 
re-exposure to iopromide.
patient was mistakenly administered iopromide again. On 
the following morning, painful, reddish papules, and 
patches admixed with vesicles recurred on the same sites 
as the previous episodes, as well as on the genitalia (Fig. 
1). For treatment, topical clobetasol propionate and 
methylprednisolone were applied for two weeks until the 
skin lesion completely disappeared, leaving pigmen-
tation. Afterward, the patient was administered iopromide 
once again and similar skin lesions appeared on the same 
areas and also on the left arm, buttock, and leg (Fig. 2). 
The skin lesions resolved after application of topical 
steroids. We advised him to avoid taking iopromide in the 
future.
DISCUSSION
All intravascular contrast media are tri-iodinated benzene 
derivatives with iodine atoms in positions 2, 4, and 6. The 
other side chains give the contrast medium high water 
solubility and low toxicity. There are currently four types 
of products, ionic monomers, ionic dimers, non-ionic 
monomers (NIM), and non-ionic dimers. Most newer 
generation products are of the NIM type, including iopro-
mide (Ultravist
Ⓡ, Shering, Berlin, Germany), iopamidol Fixed Drug Eruption due to Iopromide (Ultravist
Ⓡ)
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Fig. 3. Chemical structure of iopromide (Ultravist
Ⓡ, Shering, 
Berlin, Germany).
(Iopamiro
Ⓡ, Bracco spa, Milano, Italy), iomeprol (Iomeron
Ⓡ, 
Bracco spa, Milano, Italy), and iohexol (Omnipaque
TM, GE 
Healthcare, USA) (Fig. 3)
3. Incidence of serious adverse 
reactions, such as anaphylaxis with the use of non-ionic 
contrast media (NICM), is lower than that with conven-
tional ionic media, because NICM are not ionized in 
blood and exhibit lower osmolarity, compared to ionic 
contrast media. On the contrary, the frequency of drug 
eruption caused by NICM is higher than that with ionic 
contrast media
4.
FDE typically has a late onset; therefore, it belongs to the 
category of delayed adverse contrast media induced 
reactions
2. The majority of late skin reactions after contrast 
media ingestion are probably T cell-mediated allergic 
reactions
5. Memory T cells are probably not circulating 
and remain only at the lesion, over the residual hyper-
pigmentation. This is the reason why the skin lesion occurs 
again on the same location and why it is so important that 
patch testing was performed on the lesion. Late reactions 
to contrast media have been shown to occur more fre-
quently (8%) than immediate reactions (4%)
6. The fre-
quency of late adverse reactions to NIM has been reported 
to be between 0.52∼23%
5. To the best of our knowledge, 
there have been only three reports of FDE caused by NIM; 
iopromide
2, iomeprol
4, and iopamidol
7 in the English litera-
ture. Two cases have documented positive reactions to 
iomeprol
4 and iopamidol
7 on the patch test. However, in 
another case, the patch test could not induce a positive 
reaction to iopromide
2, as in our case.
Unfortunately, we observed a negative patch test with 
iopromide. The clinical information we obtained from the 
negative results is less clear since it has recently been 
shown that negative results are of low predictive value
2. 
The negative patch test results might be attributed to the 
reagent preparation, vehicle used, inadequate transepider-
mal absorption, and testing for the responsible agent 
outside of the lesional area. Although the patch test was 
negative in our case, we could confirm the diagnosis of 
FDE due to iopromide because the skin lesion occurred 
again at the same area after re-exposure to the same drug.
In addition, some cases have suggested the possibility of 
cross-sensitization among NICMs of similar structure
2,6. 
Therefore, dermatologists and radiologists should keep in 
mind that NICM, such as iopromide, can cause FDE, and 
avoidance of the causative agent is the most useful me-
thod. In addition, patch testing with other contrast media 
should be performed for definite identification of both 
cross-sensitizing and non sensitizing contrast media
2. We 
recommended that our patient undergo patch testing with 
other contrast media; however, he did not want further 
evaluation. Last, in order to prevent cutaneous reactions, 
patients who have previously undergone a series of FDE 
to contrast media are recommended to receive admini-
stration of intravenous injections of antihistamine and cor-
ticosteroid prior to future angiography
5,6. 
REFERENCES
1. Shear NH, Knowles SR, Shapiro L. Cutaneous reactions to 
drugs. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, 
Paller AS, Leffell DJ, editors. Fitzpatrick’s dermatology in 
general medicine. 7th ed. New York, USA: McGraw-Hill, 
2007:359-360.
2. Böhm I, Medina J, Prieto P, Block W, Schild HH. Fixed drug 
eruption induced by an iodinated non-ionic X-ray contrast 
medium: a practical approach to identify the causative agent 
and to prevent its recurrence. Eur Radiol 2007;17:485-489.
3. Christiansen C. X-ray contrast media--an overview. Toxicology 
2005;209:185-187.
4. Watanabe H, Sueki H, Nakada T, Akiyama M, Iijima M. 
Multiple fixed drug eruption caused by iomeprol (Iomeron), 
a nonionic contrast medium. Dermatology 1999;198:291-294.
5. Webb JA, Stacul F, Thomsen HS, Morcos SK, et al; Members 
Of The Contrast Media Safety Committee of The European 
Society of Urogenital Radiology. Late adverse reactions to 
intravascular iodinated contrast media. Eur Radiol 2003;13: 
181-184.
6. Schick E, Weber L, Gall H. Delayed hypersensitivity reaction 
to the non-ionic contrast medium iopromid. Contact 
Dermatitis 1996;35:312.
7. Yamauchi R, Morita A, Tsuji T. Fixed drug eruption caused 
by iopamidol, a contrast medium. J Dermatol 1997;24: 
243-245.